These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32535891)

  • 1. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
    Agur Z; Elishmereni M; Foryś U; Kogan Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to select cancer patients for immunotherapy.
    Pfeiffer P; Qvortrup C; Hansen KH
    EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
    [No Abstract]   [Full Text] [Related]  

  • 5. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 6. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years.
    Koulouris A; Tsagkaris C; Nikolaou M
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33672017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of Immune Oncology: Challenges and Opportunities.
    Cesano A; Marincola FM; Thurin M
    Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
    Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
    Front Immunol; 2020; 11():223. PubMed ID: 32133005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy: broadening the scope of targetable tumours.
    van den Bulk J; Verdegaal EM; de Miranda NF
    Open Biol; 2018 Jun; 8(6):. PubMed ID: 29875199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.
    Moradi A; Pourseif MM; Jafari B; Parvizpour S; Omidi Y
    Pharmacol Res; 2020 Jun; 156():104790. PubMed ID: 32278043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy.
    Enderling H; Alfonso JCL; Moros E; Caudell JJ; Harrison LB
    Trends Cancer; 2019 Aug; 5(8):467-474. PubMed ID: 31421904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
    Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
    Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures.
    Zeng D; Ye Z; Shen R; Yu G; Wu J; Xiong Y; Zhou R; Qiu W; Huang N; Sun L; Li X; Bin J; Liao Y; Shi M; Liao W
    Front Immunol; 2021; 12():687975. PubMed ID: 34276676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.